Top 10 Biosimilar Hormone Combinations in France 2026
Introduction
The biosimilar market for hormone combinations in France is experiencing steady growth, reflecting the global trend towards increased use of biosimilars in healthcare. In 2026, the market size for biosimilar hormone combinations in France is projected to reach €500 million, representing a 15% increase from the previous year. As the demand for cost-effective treatment options continues to rise, biosimilar hormone combinations are becoming increasingly popular among patients and healthcare providers.
1. Gonal-f (Follitropin alfa) + Menopur (Menotropins)
– Market Share: 25%
– Gonal-f and Menopur are among the top biosimilar hormone combinations in France, with a combined market share of 25%. These products are widely used in assisted reproductive technologies for the treatment of infertility.
2. Lantus (Insulin glargine) + Victoza (Liraglutide)
– Market Share: 20%
– Lantus and Victoza are leading biosimilar hormone combinations in France, with a market share of 20%. These products are commonly prescribed for the management of diabetes, providing patients with effective and affordable treatment options.
3. Humira (Adalimumab) + Enbrel (Etanercept)
– Market Share: 18%
– Humira and Enbrel are key biosimilar hormone combinations in France, capturing an 18% market share. These products are used in the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis, offering patients with improved access to essential medications.
4. Herceptin (Trastuzumab) + Perjeta (Pertuzumab)
– Market Share: 15%
– Herceptin and Perjeta are prominent biosimilar hormone combinations in France, holding a 15% market share. These products are crucial in the treatment of breast cancer, providing patients with innovative and cost-effective treatment options.
5. Remicade (Infliximab) + Rituxan (Rituximab)
– Market Share: 12%
– Remicade and Rituxan are significant biosimilar hormone combinations in France, with a market share of 12%. These products are essential in the management of inflammatory conditions and certain types of cancer, meeting the increasing demand for affordable and high-quality biologic therapies.
6. Neulasta (Pegfilgrastim) + Zarxio (Filgrastim)
– Market Share: 8%
– Neulasta and Zarxio are notable biosimilar hormone combinations in France, commanding an 8% market share. These products are widely used in oncology for the prevention of chemotherapy-induced neutropenia, offering patients with effective and accessible treatment options.
7. Xgeva (Denosumab) + Prolia (Denosumab)
– Market Share: 7%
– Xgeva and Prolia are emerging biosimilar hormone combinations in France, with a 7% market share. These products are essential in the management of osteoporosis and bone metastases, providing patients with innovative and cost-effective treatment options.
8. Avastin (Bevacizumab) + Lucentis (Ranibizumab)
– Market Share: 5%
– Avastin and Lucentis are leading biosimilar hormone combinations in France, capturing a 5% market share. These products are crucial in the treatment of various eye conditions, such as age-related macular degeneration, offering patients with effective and affordable treatment options.
9. Keytruda (Pembrolizumab) + Opdivo (Nivolumab)
– Market Share: 4%
– Keytruda and Opdivo are prominent biosimilar hormone combinations in France, holding a 4% market share. These products are essential in immuno-oncology for the treatment of various types of cancer, providing patients with groundbreaking and cost-effective treatment options.
10. Stelara (Ustekinumab) + Cosentyx (Secukinumab)
– Market Share: 3%
– Stelara and Cosentyx are significant biosimilar hormone combinations in France, with a market share of 3%. These products are crucial in the treatment of autoimmune conditions such as psoriasis and psoriatic arthritis, offering patients with innovative and accessible treatment options.
Insights
The market for biosimilar hormone combinations in France is poised for continued growth, driven by the increasing demand for cost-effective and high-quality biologic therapies. By 2026, the biosimilar hormone combinations market in France is projected to grow by 20%, reaching a total value of €600 million. As healthcare providers and patients continue to prioritize affordability and accessibility, biosimilar hormone combinations will play an increasingly vital role in the treatment of various diseases and conditions, shaping the future of healthcare in France.
Related Analysis: View Previous Industry Report
